The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
Alexander A BerezinZeljko ObradovicIvan M FushteyTetiana A BerezinaEvgen V NovikovLukas SchmidbauerMichael LichtenauerAlexander E BerezinPublished in: Biomedicines (2023)
the levels of adropin seem to be a predictor for the favorable modification of hemodynamic performances during SGLT2 inhibition, independent ofN-terminal brain natriuretic pro-peptide levels.